PDS Biotechnology Corp

EU6

Company Profile

  • Business description

    PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

  • Contact

    303A College Road
    East PrincetonNJ08540
    USA

    T: +1 800 208-3343

    E: [email protected]

    https://www.pdsbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    21

Stocks News & Analysis

stocks

ASX healthcare share undervalued post earnings

Short term headwinds mask long term value opportunity.
stocks

ASX energy share sees 363% increase in dividend

Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,338.8054.50-0.58%
CAC 408,473.5134.310.41%
DAX 4026,245.1321.01-0.08%
Dow JONES (US)53,577.40160.240.30%
FTSE 10010,878.747.42-0.07%
HKSE25,689.43178.330.70%
NASDAQ26,151.30171.110.66%
Nikkei 22566,262.16405.730.62%
NZX 50 Index14,013.2120.490.15%
S&P 5007,677.2824.420.32%
S&P/ASX 2009,127.8055.90-0.61%
SSE Composite Index3,912.5223.080.59%

Market Movers